Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP331704.RAx17KjsuEvtUS2hXiZhPFvCGl7upK3iF_HerpHSL43fM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP331704.RAx17KjsuEvtUS2hXiZhPFvCGl7upK3iF_HerpHSL43fM130_assertion type Assertion NP331704.RAx17KjsuEvtUS2hXiZhPFvCGl7upK3iF_HerpHSL43fM130_head.
- NP331704.RAx17KjsuEvtUS2hXiZhPFvCGl7upK3iF_HerpHSL43fM130_assertion description "[This specifically applies to children with severe congenital neutropenia who receive lifelong treatment with G-CSF and in which the high susceptibility to develop MDS and acute myeloid leukemia (AML) has now become a major clinical concern.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP331704.RAx17KjsuEvtUS2hXiZhPFvCGl7upK3iF_HerpHSL43fM130_provenance.
- NP331704.RAx17KjsuEvtUS2hXiZhPFvCGl7upK3iF_HerpHSL43fM130_assertion evidence source_evidence_literature NP331704.RAx17KjsuEvtUS2hXiZhPFvCGl7upK3iF_HerpHSL43fM130_provenance.
- NP331704.RAx17KjsuEvtUS2hXiZhPFvCGl7upK3iF_HerpHSL43fM130_assertion SIO_000772 20237318 NP331704.RAx17KjsuEvtUS2hXiZhPFvCGl7upK3iF_HerpHSL43fM130_provenance.
- NP331704.RAx17KjsuEvtUS2hXiZhPFvCGl7upK3iF_HerpHSL43fM130_assertion wasDerivedFrom befree-20150227 NP331704.RAx17KjsuEvtUS2hXiZhPFvCGl7upK3iF_HerpHSL43fM130_provenance.
- NP331704.RAx17KjsuEvtUS2hXiZhPFvCGl7upK3iF_HerpHSL43fM130_assertion wasGeneratedBy ECO_0000203 NP331704.RAx17KjsuEvtUS2hXiZhPFvCGl7upK3iF_HerpHSL43fM130_provenance.